Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON 86 MM
- 21 Feb 2017 This study has been completed in Belgium.
- 24 Mar 2012 Additional location (Belgium) added as reported by European Clinical Trials Database record.
- 24 Mar 2012 Planned number of patients changed from 72 to 84 as reported by European Clinical Trials Database record.